Context Therapeutics Shares Rise After Positive Data from ONA-XR in Early Breast Cancer
Dec 10, 2021 By MarketDepth
Context Therapeutics Inc. (NASDAQ: CNTX) stock is up about 12% after the biopharmaceutical Company announced that data from the window-of-opportunity clinical trial of onapristone extended release (ONA-XR) in postmenopausal patients with progesterone receptor positive (PR+) early breast cancer demonstrated ONA-XR significantly increased suppression of tumor cell proliferation. The data were presented today during the 2021 San Antonio Breast Cancer Symposium (SABCS).
“The data from the ONAWA trial signal the potential of ONA-XR to help inhibit tumor proliferation and shift tumors to a more endocrine treatment-sensitive phenotype during treatment prior to surgery in postmenopausal women with operable breast cancer and improve overall prognosis for these patients. These results support further evaluation of ONA-XR in the treatment of early breast cancer.”
co-principal investigator Meritxell Bellet, M.D., Ph.D., medical oncologist at Vall d’Hebron University Hospital in Barcelona and an executive board member of SOLTI
The Phase 0 open-label, single-arm, multicenter ONAWA (SOLTI-1802) trial conducted by Spanish cancer research group SOLTI, enrolled 10 patients with ER+/PR+/HER2- negative tumors and levels of the cell proliferation marker “Ki67” above 10% to evaluate ONA-XR by the rate of Complete Cell Cycle Arrest (CCCR) determined by Ki-67 (≤2.7%) when administered for three weeks prior to surgery (Abstract #511).
“ONA-XR is being evaluated in four investigator-sponsored clinical trials in hormone-driven breast, ovarian and endometrial cancers. This readout is the first for the novel PR antagonist, and the results are encouraging early evidence of the potential of ONA-XR to offer a new therapeutic option for hormone-dependent cancers. We look forward to data updates from three other ONA-XR trials in 2022.”
Martin Lehr, CEO of Context Therapeutics
